Cross Sectional Study
Real-world clinical outcomes of anticancer treatments in patients with advanced melanoma in China: retrospective, observational study
Authors:
Chuanliang Cui,
Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Chuanliang
MD
Xieqiao Yan,
Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Xieqiao
MD
Shusen Liu,
Department of Medical Oncology, MSD China, Beijing, CN
About Shusen
MD
Anne C. Deitz,
Department of Medical Oncology, Merck & Co. Inc., Kenilworth, NJ, US
About Anne C.
PhD
Lu Si,
Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Lu
MD
Zhihong Chi,
Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Zhihong
MD
Xinan Sheng,
Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Xinan
MD
Bin Lian,
Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Bin
MD
Jianfeng Li,
Department of Medical Oncology, MSD China, Beijing, CN
About Jianfeng
MD
Jun Ge,
Department of Medical Oncology, MSD China, Beijing, CN
About Jun
MD
Xuan Wang,
Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Xuan
MD
Lili Mao,
Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Lili
MD
Bixia Tang,
Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Bixia
MD
Li Zhou,
Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Li
MD
Xue Bai,
Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Xue
MD
Siming Li,
Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Siming
MD
Ben Li,
Department of Medical Oncology, MSD China, Beijing, CN
About Ben
MD
Haiyan Wu,
Department of Medical Oncology, MSD China, Beijing, CN
About Haiyan
MD
Jun Guo
Department of Urology and Melanoma, Peking University Cancer Hospital & Institute, 52 # Fucheng Road, Haidian District, Beijing, CN
About Jun
MD
Abstract
Introduction: Treatment options for advanced melanoma in China are lacking, particularly second-line therapies. The aim of this retrospective observational study was to describe the real-world effectiveness of available anticancer therapies in patients with locally advanced/metastatic melanoma in China.
Methods: Adult patients with unresectable stage III or IV melanoma treated between January 1, 2014, and December 31, 2015, at the Beijing Cancer Hospital (BCH) were eligible (data cutoff: December 31, 2017). Data were obtained from patient electronic medical records. Responders were adjudicated per Response Evaluation Criteria in Solid Tumors, version 1.1. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method.
Results: Of 248 eligible patients, 221 and 116 were treated with anticancer therapies in first-line and second-line settings, respectively (89 received both at BCH). Approximately 95% of patients had stage IV melanoma; 40.7% had acral melanoma, and 30.6% had mucosal histology. By data cutoff, 195 of 248 (78.6%) patients had died. Median OS for all patients was 10.5 months; 12-month OS rate was 43.9%. In the first-line setting, the objective response rate was 6.3% (95% confidence interval, 3.5%–10.4%) and the median duration of response was 9.1 months. Median PFS was 3.5 months and 12-month PFS rate was 10.6%; median OS was 10.5 months and 12-month OS rate was 43.5%. In the second-line setting, objective response rate was 3.4% (95% confidence interval, 0.9%–8.6%) and median duration of response was 7.5 months. Median PFS was 2.3 months and 12-month PFS rate was 5.2%; median OS was 7.5 months and 12-month OS rate was 30.5%.
Conclusion: In China, first-line and second-line anticancer therapy seems to be associated with suboptimal clinical outcomes in advanced melanoma, indicating a need for effective therapies.
How to Cite:
Cui C, Yan X, Liu S, Deitz AC, Si L, Chi Z, et al.. Real-world clinical outcomes of anticancer treatments in patients with advanced melanoma in China: retrospective, observational study. International Journal of Surgery: Oncology. 2019;4(6):e76. DOI: http://doi.org/10.1097/IJ9.0000000000000076
Published on
24 Oct 2019.
Peer Reviewed
Downloads